Raphaëlle A.
- Country
- France
- Department
- Hematology and cell therapy
Research Overview
- Phase 2 Study on Zanubrutinib and BGB-11417 Efficacy and Tolerance in Previously Treated Waldenström Macroglobulinemia Patients
- FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
- Phase 3 Multicenter Randomized Trial of Venetoclax, Obinutuzumab, and Pirtobrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data & Insights
Has run more than one trial at 25 of 175 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), focusing on innovative therapeutic approaches for previously untreated patients.
- Blood Cancer Treatment
- Lymphoid Malignancies
- Novel Therapy Combinations
Their research centers on evaluating treatment durations and combinations for optimal patient outcomes in blood cancers.
Personalized Medicine
The investigator explores minimal residual disease (MRD) guided treatment approaches, developing strategies for individualizing therapy duration based on patient response.
- Treatment Duration Optimization
- Response-Guided Therapy
- Patient Monitoring Strategies
Their work advances precision medicine approaches in hematologic malignancies through response-adapted treatment protocols.
Therapeutic Innovation
The investigator studies targeted therapies including venetoclax, obinutuzumab, and pirtobrutinib combinations for blood cancer treatment.
- Novel Drug Combinations
- Fixed-Duration Protocols
- Treatment Efficacy Assessment
Their research evaluates comparative effectiveness of different therapeutic combinations in leukemia and lymphoma.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.